Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: L. Kandolf Sekulovic, J. Guo, S. Agarwala, A. Hauschild, G. McArthur, G. Cinat, A. Wainstein, C. Caglevic, P. Lorigan, H. Gogas, M. Alvarez, R. Duncombe, C. Lebbe, K. Peris, P. Rutkowski, A. Stratigos, A.-M. Forsea, L. De La Cruz Merino, M. Kukushkina, R. Tags: Original Research Source Type: research
More News: Argentina Health | Australia Health | Brazil Health | Cancer | Cancer & Oncology | Chile Health | China Health | Dermatology | Melanoma | Mexico Health | Skin | Skin Cancer | Study